Investor Presentaiton

Investor Presentation First nine months of 2018 In PIONEER 8, oral sema showed statistically significant reductions in HbA1c, body weight and total insulin dose¹ Reduction in HbA1c Reduction in body weight (kg) Slide 11 Change in total insulin dose³ HbA1c reduction (%)² Placebo Oral sema Weight loss (kg) 2 Change in insulin unit (IU/day)² 3 7 14 3 7 14 3 7 14 Placebo Placebo Placebo mg mg mg mg mg mg mg mg mg 0.0 1.0 0.6kg 12 10 0.0% 0.0 -0.3 80 -1.0 -0.6 -0.5%* -1.0 kg* -2.0 -0.9 -0.8%* 4 2 0 -3.0 -2.9 kg* -1.2 -4.0 -1.2%* -1.5 -5.0 -4.3kg* -8 -6* -7* 1 Only 7 mg and 14 mg oral semaglutide showed reduction in end of trial insulin dose 2 Results illustrated by using the secondary statistical method called hypothetical estimand after 52 weeks of treatment: Treatment effect, if all participants followed the treatment without rescue medication (analysed by using Mixed Models for Repeated Measurements (MMRM)). The statistical method is consistent with e.g. the statistical method used for the SUSTAIN programme for subcutaneous semaglutide 3 At end of trial period *Statistically significant vs placebo Sema: semaglutide novo nordisk

View entire presentation